A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of Plerixafor (0.24 mg/kg) Plus G CSF (10 µg/kg) Versus G CSF (10 µg/kg) Plus Placebo to Mobilize and Collect ≥5 × 106 CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Filgrastim (Primary) ; Plerixafor (Primary)
- Indications Stem cell mobilisation
- Focus Therapeutic Use
- Sponsors Sanofi
- 14 Jun 2015 Results presented at the 20th Congress of the European Haematology Association.
- 30 Apr 2015 New trial record